Could a designer probiotic tame IBD Flare-Ups?
NCT ID NCT07318753
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a specially selected probiotic (LR607) in 300 people with mild-to-moderate ulcerative colitis, a form of inflammatory bowel disease. The probiotic is designed to boost a natural gut pathway (NOD2) that helps control inflammation. The goal is to see if adding LR607 to standard treatment can improve symptoms and reduce disease activity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASE (IBD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shenzhen Hospital of Southern Medical University
Shenzhen, Guangdong, 518000, China